Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Aug;23(4):993-1002.
doi: 10.1007/s10238-022-00936-8. Epub 2022 Nov 15.

Presepsin levels and COVID-19 severity: a systematic review and meta-analysis

Matteo Guarino  1 , Benedetta Perna  1 , Martina Maritati  2 , Francesca Remelli  3 , Caterina Trevisan  3 , Michele Domenico Spampinato  1 , Anna Costanzini  1 , Stefano Volpato  3 , Carlo Contini  2 , Roberto De Giorgio  4
Affiliations
Meta-Analysis

Presepsin levels and COVID-19 severity: a systematic review and meta-analysis

Matteo Guarino et al. Clin Exp Med. 2023 Aug.

Abstract

Plasmatic presepsin (PSP) is a novel biomarker reported to be useful for sepsis diagnosis and prognosis. During the pandemic, only few studies highlighted a possible correlation between PSP and COVID-19 severity, but results remain inconsistent. The present study aims to establish the correlation between PSP and COVID-19 severity. English-language papers assessing a correlation between COVID-19 and PSP from MEDLINE, PubMed, Google Scholar, Cochrane Library, MeSH, LitCovid NLM, EMBASE, CINAHL Plus and the World Health Organization (WHO) website, published from January 2020 were considered with no publication date limitations. Two independent reviewers performed data abstraction and quality assessment, and one reviewer resolved inconsistencies. The protocol was registered on PROSPERO (CRD42022325971).Fifteen articles met our eligibility criteria. The aggregate study population included 1373 COVID-19 patients who had undergone a PSP assessment. The random-effect meta-analysis was performed in 7 out of 15 selected studies, considering only those reporting the mean PSP levels in low- and high-severity cases (n = 707).The results showed that the pooled mean difference of PSP levels between high- and low-severity COVID-19 patients was 441.70 pg/ml (95%CI: 150.40-732.99 pg/ml).Our data show that presepsin is a promising biomarker that can express COVID-19 severity.

Keywords: COVID-19; Disease severity; Presepsin; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
PRISMA 2020 flowchart for new systematic reviews that included only database and registry searches
Fig. 2
Fig. 2
Forest plot on the mean difference of PSP levels between the high- and low-severity patient groups from the random-effect meta-analysis
See this image and copyright information in PMC

References

    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. World Health Organisation. https://covid19.who.int/ (accessed 09 June 2022).
    1. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5. - DOI - PMC - PubMed
    1. Vahidy FS, Drews AL, Masud FN, Schwartz RL, Askary BB, Boom ML, Phillips RA. Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston metropolitan area. JAMA. 2020;324:998–1000. doi: 10.1001/jama.2020.15301. - DOI - PMC - PubMed
    1. Rotondo JC, Martini F, Maritati M, Mazziotta C, Di Mauro G, Lanzillotti C, Barp N, Gallerani A, Tognon M, Contini C. SARS-CoV2 infection: new molecula, phylogenetic and pathogenetic insight efficacy of current vaccines and the potential risk of variants. Viruses. 2021;13:1687. doi: 10.3390/v13091687. - DOI - PMC - PubMed